Abstract：ObjectiveTo explore the effect of Levosimendan associated with blood purification in the treatment of refractory heart failure.Methods80 patients with refractory heart failure who were treated in EICU of our hospital from July 2015 to February 2017 were selected and divided into the control group and the treatment group according to the method of odd and even random grouping,40 cases in each group.The control group was given Dobutamine Torasemide and (or)Furosemide on the basis of conventional heart failure drugs.The treatment group was treated with Levosimendan and blood purification on the basis of routine drugs treatment for heart failure.The level of leftventricular ejection fraction(LVEF),cardiac output index (CI)and NT-proBNP were compared before and after treatment between the two groups.ResultsThe total effective rate after treatment in the treatment group was significantly higher than that in the control group,with significant difference (P＜0.05),the level of LVEF and CI after treatment in the treatment group was significantly higher than that in the control group,the level of NT-proBNP after treatment in the treatment group was lower than that in the control group,with significant difference(P＜0.05).ConclusionThe effect of Levosimendan associated with blood purification in the treatment of refractory heart failure is significant,which is worth applying in clinical.
Torbricki A，Perrier A，Konstantinides S，et al.Guidelines on the diagnosis and management of acute pulmonary embolism：the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology（ESC）[J].Eur Heart J，2008，29（18）：2276-2315.
Cleland JG，Nilitin N，Mcgowan J.Levosimendan：first in a new class of inodilator for acute and chronic severe heart failure[J]Expert Rev Cardiovasc Ther，2004，2（1）：9-19.
[11]
Paraskevaidis IA，Parissis JT，Th Krenmstinos D.Anti-inflammatory and anti-apapteric effects of levosimendan in decomensated heart failure：a novel mechanism of drug-induced improvement in comtractile performance of the failing heart[J].Curr Med Chem Cardiovasc Hematol Agents，2005，3（3）：243-247.
[12]
Kyrzopeulos S，Adamopoulos S，Pariasis JT，et al.LevosimendanreducesplasmaB-typenatriureticpeptideandinterleukin 6，and improves central hemodynamics in severe heart failure patients[J].Int J Cardiol，2005，99（3）：409-413.
[13]
Avgeropoulou C，Andreadou I，Markantonis-Kyroudis S，et al.The Ca2+zensitizer levosimendan improves oxidative damage，BNP and pro-inflammatory cytokine level in patients with advanced decompensated heart failure in comparison to dobutamine[J].Eur J Heart Fail，2005，7（5）：882-887.
京公网安备 11010502046607号